Latest News

Morgan Stanley says flu vaccine data is likely to boost Moderna’s stock

59 views0
By
Share

Moderna’s phase 2 trial data for its flu vaccine is expected early this year and could push the stock higher.

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0
Previous
Next

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:Latest News